|
The Ethics of Underpowered Trials
|
|
11
|
195
|
July 2, 2026
|
|
Randomized non-comparative trials: an oxymoron?
|
|
85
|
4840
|
June 24, 2026
|
|
Statin-related side effects: the recent Lancet publication is biased toward false-negatives
|
|
34
|
889
|
June 21, 2026
|
|
French target trial using obs data of HCQ vs not in SARS-CoV-2 infection
|
|
6
|
3377
|
June 17, 2026
|
|
Reanalyzing MERIT design using Julia + recent numerical algorithms
|
|
3
|
241
|
June 13, 2026
|
|
Relaxing Assumptions and Targeted Estimands with MOST
|
|
12
|
243
|
May 27, 2026
|
|
A Longitudinal Renal Health Outcome for Clinical Trials in Acute Kidney Injury?
|
|
15
|
214
|
May 22, 2026
|
|
The growing interest in integrating causal inference and Design Theory
|
|
13
|
565
|
May 16, 2026
|
|
Best model reduction approach for Fine-Gray prediction model
|
|
5
|
111
|
March 27, 2026
|
|
Scoping review + SOCI: to assess DHIS2 applicability for NCD
|
|
2
|
77
|
March 26, 2026
|
|
FDA Draft Guidance: Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products
|
|
10
|
1039
|
March 2, 2026
|
|
One-sided significance threshold of less than 0.1 in Phase 2 clinical trial
|
|
7
|
159
|
February 25, 2026
|
|
Bootstrapped variable selection in the presence of competing risk
|
|
7
|
156
|
January 12, 2026
|
|
Should causal modeling be a required part of a NIH grant applications?
|
|
1
|
125
|
December 17, 2025
|
|
Cause-Agnostic RCT (CAR)
|
|
9
|
502
|
December 12, 2025
|
|
A High-Fiber Plant-Based Diet in Myeloma Precursor Disorders – Results from the 2 NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
|
|
2
|
111
|
December 11, 2025
|
|
MICE Imputation Models
|
|
10
|
467
|
December 6, 2025
|
|
NEJM Trial - proportional hazard assumption
|
|
12
|
456
|
December 1, 2025
|
|
The Design Theory /Causal Inference Divide Explained by the Position of U
|
|
2
|
173
|
November 28, 2025
|
|
Rarity Roulette: A simulator for estimating hypothetical outcomes spreads for mass screenings
|
|
2
|
108
|
November 20, 2025
|
|
Individual response
|
|
266
|
49422
|
November 17, 2025
|
|
When and why (not) to worry about the PO assumption
|
|
4
|
729
|
October 9, 2025
|
|
Comparing multiple groups to a reference group
|
|
7
|
245
|
October 6, 2025
|
|
Bayesian Clinical Trials: Interview with Frank Harrell
|
|
0
|
251
|
September 18, 2025
|
|
Estimating the probability of neonatal sepsis with plug-in incidence
|
|
6
|
161
|
September 11, 2025
|
|
Fine-Gray vs Cause-Specific Cox Regression
|
|
0
|
191
|
September 11, 2025
|
|
Sample Size Calculation for a 2x2 Factorial RCT
|
|
6
|
450
|
September 3, 2025
|
|
Table 2 Fallacy?: Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
|
|
32
|
4318
|
August 12, 2025
|
|
Illogic of Weighting While Estimating Model Parameters
|
|
13
|
834
|
August 11, 2025
|
|
Statistical Process Control and Experimental Design
|
|
9
|
480
|
May 13, 2025
|